Global Phenobarbital Market: Introduction
Phenobarbital is a long-acting barbiturate, an anti-epileptic medication (AED) that sedates the nervous system. It is generally prescribed by health care professionals to avoid seizures or to ease anxiety. Phenobarbital is often recommended to treat disorders such as epilepsy and seizure because the drug stabilizes electrical activity in the brain. Phenobarbital is a drug class known as anticonvulsants /hypnotics barbiturate. This medication is also used for a brief period of time (generally not more than 2 weeks) to assist individuals to calm down or help them sleep during anxiety periods. It operates to trigger calming by influencing certain components of the brain. Phenobarbital is taken by mouth in the form of tablet or an elixir (liquid). Usually, its dosage is one to three times a day.
Global Phenobarbital Market: Competitive Landscape
Founded in 1996, Novartis AG is among the top global pharmaceutical companies operating across all the regions in almost all the specialties. Novartis operates in patented pharmaceutical products, generic pharmaceuticals & biosimilars, and surgical and vision care segments. It offers many OTC as well as generic drugs for acute attack treatment of migraine. The company is investing into specialty prophylactic treatment drugs through its recent acquisitions and strategic collaborations.
Request Brochure of the Report:
Other key players operating in the global Phenobarbital market include AstraZeneca Plc., Allergan Plc., GlaxoSmithKline Plc., Eli Lilly & Company, Merck & Co., Inc., Arrow Pharmaceuticals, Janssen Pharmaceutical Company (Johnson & Johnson), and Dainippon Sumitomo Pharma.
Global Phenobarbital Market: Dynamics
High Prevalence of Epilepsy to Drive Market
Epilepsy is a chronic neurological disorder with approximately 50 million patient population. The growing incidence of illnesses is expected to increase the demand for epilepsy treatment and hence, the phenobarbital market.
Rise in Geriatric Population to Boost Market
Epilepsy is common among both kids and adults. However, elderly population is more likely to be impacted by this disorder. It is predicted that increase in geriatric population is likely to increase demand for epilepsy treatment. This, in turn, is expected to boost the phenobarbital market in the next few years.